Alzinova AB
78D
Company Profile
Business description
Alzinova AB is a Swedish biotechnology company engaged in the discovery and development of therapeutics for the treatment of Alzheimer's disease. The company is developing ALZ-101, an oligomer-specific therapeutic vaccine currently advancing toward Phase 2 clinical development, and ALZ-201, a monoclonal antibody targeting toxic amyloid-beta (AB) oligomers, which is in preclinical development. The company's proprietary ABCC peptide technology is focused on disease-modifying treatments for Alzheimer's disease.
Contact
Entreprenorsstraket 10
GoCo House
Molndal431 53
SWESector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
7
Stocks News & Analysis
stocks
The best AI stocks to buy now
Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,857.20 | 34.00 | 0.39% |
| CAC 40 | 7,729.69 | 39.52 | -0.51% |
| DAX 40 | 24,806.97 | 297.39 | -1.18% |
| Dow JONES (US) | 51,231.64 | 51.77 | 0.10% |
| FTSE 100 | 10,441.60 | 16.90 | -0.16% |
| HKSE | 24,070.62 | 284.83 | 1.20% |
| NASDAQ | 27,193.34 | 345.35 | -1.25% |
| Nikkei 225 | 68,667.71 | 374.40 | -0.54% |
| NZX 50 Index | 13,699.66 | 7.81 | 0.06% |
| S&P 500 | 7,765.36 | 36.41 | -0.47% |
| S&P/ASX 200 | 8,695.70 | 34.80 | 0.40% |
| SSE Composite Index | 3,784.93 | 26.97 | -0.71% |